Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877974 | 1.00 | MAOA (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL30904862 | 1.00 | MAOA (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL30963324 | 0.87 | RECQL (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL2066283 | 0.87 | RECQL (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL2066285 | 0.87 | RECQL (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL30497421 | 0.86 | HPGD (0.51) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL23052958 | 0.84 | LMNA (0.58) | MAOAMAOBLMNARECQLRAB9A | |
| SCHEMBL1528647 | 0.83 | MAOA (0.55) | MAOAMAOBLMNARECQLAR | |
| SCHEMBL1528645 | 0.83 | MAOA (0.55) | MAOAMAOBLMNARECQLAR | |
| SCHEMBL30867035 | 0.83 | MAOA (0.55) | MAOAMAOBLMNARECQLAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221690-A | Chromone pyridazine compound and synthetic method and application thereof | 昆明理工大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-118005593-A | Preparation method of 2, 3-disubstituted chromone compound | 昆明理工大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-116514758-A | Chromone derivative and synthesis method thereof | 南京工业大学 | 2023-08-01 | — | — | CN | disclosed |
| WO-2015114102-A1 | SILYL SUBSTITUTED AZADIBENZOFURANS AND AZADIBENZOTHIOPHENES | BASF SE (DE) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015114102-A1 | SILYL SUBSTITUTED AZADIBENZOFURANS AND AZADIBENZOTHIOPHENES | BASF SE (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | MAOA 471/4885MAOB 399/4885LMNA 616/4885 |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | MAOA 471/4885MAOB 399/4885LMNA 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.